Grant: Engage Grants Program
University of Ottawa
$25,000.00
Improving the cryopreservation process for umbilical cord blood
EF 2011-12
Résumé
Human umbilical cord blood (UCB) is a convenient source of hematopoietic stem cells and is an alternative to
bone marrow for transplants. UCB has been successfully utilized to treat a variety of blood disorders and
malignancies in children and adults. Use of allogeneic cord blood is becoming more routine in the clinical
setting and has been used in more than 25,000 allogeneic cord blood transplants. It is estimated that there are
over 550,000 UCB samples available from the international network of public cord blood banks. While the
total number of UCB transplants is less than bone marrow transplants, there has been a dramatic increase in
UCB transplants since 2005 when only 3700 transplants had been performed with approximately 100,000 UCB
units in storage. This trend is expected to increase into the future as the population continues to age and
regenerative medicine therapies become more routine in the clinical setting. Dimethyl sulphoxide (DMSO) is
the most commonly used cryoprotectant for the preservation of UCB. While current cryopreservation protocols
are clinically effective, they may not be optimal. DMSO is toxic to cells and cryopreservation protocols
include steps to minimize this toxicity, such as introducing DMSO to the cells at low temperatures and
minimizing the time the cells are exposed to DMSO before freezing. Further, patients receiving UCB
sometimes suffer adverse reactions to the DMSO in the product. The optimization of UCB cryopreservation,
through the reduction, or elimination, of DMSO and its toxic effects, would be beneficial to both the UCB
banking and transplant communities. This project describes a collaborative effort between the largest private
cord blood banking company in Canada and a University laboratory, to optimize UCB cryopreservation using
novel inhibitors of ice recrystallization. The proposed work from this study will enhance the quality of
cryopreserved UCB samples and increase the likelihood of successful transplant in the clinical setting.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
419282-2011
Name nom
Ben, Robert
Department département
Chemistry
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3705
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Bio-organic chemistry
Research subject fr
Chimie bio-organique
Partie
1
Nb partie
1
Application title
Improving the cryopreservation process for umbilical cord blood
Keyword
NSERC
Application summary
Human umbilical cord blood (UCB) is a convenient source of hematopoietic stem cells and is an alternative to
bone marrow for transplants. UCB has been successfully utilized to treat a variety of blood disorders and
malignancies in children and adults. Use of allogeneic cord blood is becoming more routine in the clinical
setting and has been used in more than 25,000 allogeneic cord blood transplants. It is estimated that there are
over 550,000 UCB samples available from the international network of public cord blood banks. While the
total number of UCB transplants is less than bone marrow transplants, there has been a dramatic increase in
UCB transplants since 2005 when only 3700 transplants had been performed with approximately 100,000 UCB
units in storage. This trend is expected to increase into the future as the population continues to age and
regenerative medicine therapies become more routine in the clinical setting. Dimethyl sulphoxide (DMSO) is
the most commonly used cryoprotectant for the preservation of UCB. While current cryopreservation protocols
are clinically effective, they may not be optimal. DMSO is toxic to cells and cryopreservation protocols
include steps to minimize this toxicity, such as introducing DMSO to the cells at low temperatures and
minimizing the time the cells are exposed to DMSO before freezing. Further, patients receiving UCB
sometimes suffer adverse reactions to the DMSO in the product. The optimization of UCB cryopreservation,
through the reduction, or elimination, of DMSO and its toxic effects, would be beneficial to both the UCB
banking and transplant communities. This project describes a collaborative effort between the largest private
cord blood banking company in Canada and a University laboratory, to optimize UCB cryopreservation using
novel inhibitors of ice recrystallization. The proposed work from this study will enhance the quality of
cryopreserved UCB samples and increase the likelihood of successful transplant in the clinical setting.